Gilead Sciences

Licence terms for the exclusive development and commercialisation rights to certain macrocyclic inhibitors of peptide bond isomerases (cyprolides) have been agreed upon by Cypralis and Gilead Sciences. Read more


Gilead Sciences is to pay $200m for infringing upon Merck and Ionis Pharmaceuticals’ Hepatitis C drug patents Read more


Quintiles and Gilead Sciences have scooped up awards in this year’s Britain’s Healthiest Company Awards Read more

Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has returned (relapsed). Read more

Aptalis Pharmaceutical Technologies has announced that the European Commission granted marketing authorisation for a new paediatric indication of a new oral granule formulation of Gilead Sciences, Inc.’s Viread for HIV infected children... Read more